TScan Gets FDA Clearance for Three Investigational New Drug Apps
January 23 2023 - 8:45AM
Dow Jones News
By Chris Wack
TScan Therapeutics Inc. said Monday that the Food and Drug
Administration has cleared its investigational new drug
applications for T-Plex, TSC-204-A0201 and TSC-204-C0702.
The Massachusetts-based clinical-stage biopharmaceutical company
said T-Plex would now be the primary investigational new drug and
TSC-204-A021 and TSC-204-C0702 the secondary investigational new
drugs for its solid-tumor program.
The company said T-Plex allows patients to customize
combinations of T-cell receptor-engineered T-cell therapies
(TCR-T), chosen from its proprietary bank of TCRs, to treat cancers
based on their specific markers. TSC-204-A0201 and TSC-204-C0702
target cancers associated with melanoma-associated antigen-1, a
cancer-associated antigen overexpressed in head, neck, melanoma,
cervical, and non-small cell lung cancers.
A Phase-1 clinical trial with a screening protocol expected to
begin in the second quarter would assess repeat-dosing of TCR-Ts,
and a secondary investigational new drug application would be filed
for each unique TCR-T referencing the T-Plex application, TScan
said.
The trial would evaluate each TCR-T as a singleplex therapy at
two successive dose levels, the company said. Once single-agent
safety is established, each TCR would become eligible for
multiplexing, or combining it with any other TCR that has passed
this threshold, the company said.
TScan shares were up 14% to $2.40 in premarket trading
Monday.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 23, 2023 08:30 ET (13:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
TScan Therapeutics (NASDAQ:TCRX)
Historical Stock Chart
From Apr 2023 to Apr 2024